Xtalks 网络研讨会：EEG 与 ERP 客观脑指标能否改善 MDD 临床试验决策？

In this free webinar, learn how electroencephalogram (EEG) and event-related potential (ERP) measures can support decision-making in major depressive disorder (MDD) clinical trials. The featured speakers will discuss their use in patient stratification, dose selection, target engagement and early pharmacodynamic assessment. Attendees will also explore limitations related to comorbidities, reproducibility, standardization and translating group-level findings into individual patient predictions.

, /PRNewswire/ -- Psychiatric drug development still leans on rating scales developed decades ago: subjective instruments that capture how a patient describes feeling but not what the brain is doing. In major depressive disorder (MDD), high patient variability, strong placebo responses and limited objective measures of treatment mechanisms can create challenges for trial design and go/no-go decisions. Electroencephalogram (EEG) and event-related potentials (ERP) offer objective, low-burden and inexpensive measures of brain function. This webinar explores where EEG and ERP can support MDD clinical trials, where they fit within a protocol and where their limitations should be considered.

The featured speakers will examine the published literature alongside their own research, including EEG signatures that can distinguish MDD patients from matched controls and track symptom severity. These signatures capture different aspects of the disorder, including cognitive function, emotional processing and behavioral attention. The panelists will discuss how these EEG signatures appear largely non-redundant, suggesting that different paradigms index different facets of the disorder and that a single "depression biomarker" may not capture this complexity. The panelists will also review evidence showing that targeted pharmacological intervention can shift these measures, positioning them as pharmacodynamic rather than exploratory tools.

The panel will focus on decisions development teams face when designing MDD clinical trials. Topics include whether EEG can improve pre-screening, inform dose selection and confirm target engagement earlier and more cost-effectively. The discussion will also address how anxiety, insomnia, disrupted sleep architecture and substance use disorders carry their own electrophysiological signatures and can confound a depression readout if left unmeasured.

The featured panelists will also discuss challenges related to reproducibility, standardization, effect sizes and the distance between group-level signal and individual patient prediction.

Register for this webinar to learn how EEG and ERP readouts can support patient stratification, dose selection and earlier treatment decisions in MDD clinical trials.

Join Derek Buhl, Scientific Director, Neuroscience Precision Medicine, AbbVie; Chris Berka, Co-founder & Chief Scientific Officer, Advanced Brain Monitoring; and Natasha Kovacevic, Senior Director, Precision Psychiatry, Advanced Brain Monitoring, for the live webinar on Thursday, November 12, 2026, at 1pm EST (12pm CST / 10 am PST).

For more information, or to register for this event, visit Can Objective Brain Measures Improve MDD Trial Decisions?.

ABOUT XTALKS

Xtalks – The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what's next.

To learn more about Xtalks, visit www.xtalks.com
For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Contact:
Soumya Shashikumar
Tel: +1 (416) 977-6555 x371
Email: [email protected]

SOURCE Xtalks